Marker uses a Multi-Antigen Recognizing T cell (MAR-T cell) technology that harnesses millions of years of immunological evolution intended to provide patients with T cells capable of recognizing multiple antigens within a tumor, with the expectation of reducing the possibility of tumor escape and enabling effective tumor cell killing.
Unlike other cellular therapies, MARKER’S MAR-T cell APPROACH does not require genetic modification offering reduced manufacturing complexity and significant cost reduction over traditional cellular therapies. Data from our clinical trials demonstrated an excellent safety profile with no ICANS and showed potential clinical benefit mediated by the infused MAR-T cell product.1, 2, 3
Marker’s lead product candidate, MT-601, recognizes six tumor-associated antigens (Survivin, PRAME, NY-ESO-1, MAGE-A4, SSX2, WT-1), which we believe will result in a potent, durable anti-tumor response. MT-601 is currently evaluated in a PHASE 1 MULTICENTER TRIAL in patients with lymphoma, who relapsed or are ineligible to receive anti-CD19 CAR-T cell therapy.
1 Vasileiou S et al. J Clin Oncol 2021. DOI: 10.1200/JCO.20.02224. 2 Lulla PD et al. Sci Transl Med 2022. DOI: 10.1126/scitranslmed.aaz3339. 3 Lulla PD et al. Blood 2021. DOI: 10.1182/blood.2020009471.
